1. |
|
|
2. |
- Phillips, E., et al.
(författare)
-
Compound specific isotope analysis in hydrogeology
- 2022
-
Ingår i: Journal of Hydrology. - : Elsevier BV. - 0022-1694. ; 615
-
Forskningsöversikt (refereegranskat)abstract
- Here, we review the contributions of Professor Barbara Sherwood Lollar to Compound Specific Isotope Analysis (CSIA) in contaminant hydrogeology and environmental chemistry. We first discuss the seminal work by Professor Sherwood Lollar's lab on establishing CSIA as a quantitative tool for contaminant (bio)transformation at contaminated groundwater sites. We describe the critical research by her lab in the development and validation of sample collection techniques, single- and multi-element CSIA, and isotope data evaluation for reliable interpretations. We highlight the contributions of Professor Sherwood Lollar's lab towards the development of best practices for the successful application of CSIA by industry to demonstrate the occurrence of (bio)transformation, identify (bio)transformation mechanisms, quantify the extent and rate of degradation and differentiate among potential contaminant sources. We then explore Professor Sherwood Lollar's applications of CSIA to hydrogeology of the deep subsurface and the fast widening of the field to new environments (e.g., sediments), contaminants (e.g., chlorofluorocarbons, pesticides), and systems (e.g., plant, enzymes).
|
|
3. |
|
|
4. |
|
|
5. |
|
|
6. |
|
|
7. |
|
|
8. |
- Hagell, Peter, et al.
(författare)
-
Apomorphine formulation may influence subcutaneous complications from continuous subcutaneous apomorphine infusion in Parkinson's disease
- 2020
-
Ingår i: Journal of Neurology. - 0340-5354 .- 1432-1459. ; 267:11, s. 3411-3417
-
Tidskriftsartikel (refereegranskat)abstract
- Continuous subcutaneous (s.c.) apomorphine infusion is an effective therapy for Parkinson's disease (PD), but a limitation is the formation of troublesome s.c. nodules. Various chemically non-identical apomorphine formulations are available. Anecdotal experiences have suggested that shifting from one of these (Apo-Go PumpFill®; apoGPF) to another (Apomorphine PharmSwed®; apoPS) may influence the occurrence and severity of s.c. nodules. We, therefore, followed 15 people with advanced PD (median PD-duration, 15 years; median "off"-phase Hoehn and Yahr, IV) on apoGPF and with troublesome s.c. nodules who were switched to apoPS. Data were collected at baseline, at the time of switching, and at a median of 1, 2.5, and 7.3 months post-switch. Total nodule numbers (P < 0.001), size (P < 0.001), consistency (P < 0.001), skin changes (P = 0.058), and pain (P ≤ 0.032) improved over the observation period. PD severity and dyskinesias tended to improve and increase, respectively. Apomorphine doses were stable, but levodopa doses increased by 100 mg/day. Patient-reported apomorphine efficacy tended to increase and all participants remained on apoPS throughout the observation period; with the main patient-reported reason being improved nodules. These observations suggest that patients with s.c. nodules caused by apoGPF may benefit from switching to apoPS in terms of s.c. nodule occurrence and severity. Alternatively, observed benefits may have been due to the switch itself. As nodule formation is a limiting factor in apomorphine treatment, a controlled prospective study comparing local tolerance with different formulations is warranted.
|
|
9. |
|
|
10. |
|
|